Advertisement

Drugs

, Volume 78, Issue 11, pp 1145–1156 | Cite as

Vismodegib: A Review in Advanced Basal Cell Carcinoma

  • James E. Frampton
  • Nicole Basset-Séguin
Adis Drug Evaluation

Abstract

Vismodegib (Erivedge®) is the first-in-class, oral small molecule inhibitor of the Hedgehog (Hh) pathway, abnormal activation of which is associated with basal cell carcinoma (BCC). In the USA, vismodegib is indicated for the treatment of adults with metastatic BCC (mBCC) or with locally-advanced BCC (LaBCC) that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. Similarly, in the EU, vismodegib is indicated for the treatment of adult patients with symptomatic mBCC, or with laBCC inappropriate for surgery or radiotherapy. The full European approval of vismodegib was based on the results of two phase II, open-label, noncomparative, international trials (ERIVANCE BCC and STEVIE), both of which showed high rates of tumour control in the indicated patient populations, including individuals with or without Gorlin syndrome. These studies also showed that vismodegib has an acceptable and manageable tolerability profile characterized by a number of class-related treatment-emergent adverse events, including muscle spasms, taste disturbances, alopecia, weight loss and asthenia (fatigue). Primary and secondary resistance to vismodegib has been documented, albeit at a low rate compared with some other targeted therapies. Vismodegib is therefore an effective and generally well tolerated systemic therapy for patients with mBCC and laBCC that can no longer be suitably controlled with surgery and/or radiotherapy. Historically, it is the first member of a class of drugs (Hh pathway inhibitors) that are now considered to be first-line treatment options for such individuals.

Notes

Acknowledgements

During the peer review process, the manufacturer of vismodegib was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

James Frampton is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest. Nicole Basset-Séguin has received grants or has grants pending (Roche, Genentech); has received consulting fees or honoraria (Roche, Novartis, Pierre Fabre, Leo Pharmaceuticals, Galderma); and has received support for study-related travel, manuscript preparation or other purposes (Galderma, Roche, Leo Pharmaceuticals).

References

  1. 1.
    Mohan SV, Chang ALS. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep. 2014;3(1):40–5.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. F1000Prime Rep. 2015; 7:53.Google Scholar
  3. 3.
    Bichakjian CK, Olencki T, Aasi SZ, et al. Basal cell skin cancer, Version 1.2018 – September 18, 2017, NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org. Accessed 6 Jul 2018.
  4. 4.
    Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. Clin Transl Oncol. 2015;17:497–503.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Fecher LA, Sharfman WH. Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors. Biologics. 2015;9:129–40.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Fecher LA. Systemic therapy for inoperable and metastatic basal cell cancer. Curr Treat Options Oncol. 2013;14:237–48.CrossRefPubMedGoogle Scholar
  7. 7.
    Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743–54.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cowey CL. Targeted therapy for advanced basal-cell carcinoma: vismodegib and beyond. Dermatol Ther (Heidelb). 2013;3:17–31.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Danhof R, Lewis K, Brown M. Small molecule inhibitors of the Hedgehog pathway in the treatment of basal cell carcinoma of the skin. Am J Clin Derm. 2017;19(2):195–207.CrossRefGoogle Scholar
  10. 10.
    Briscoe J, Thérond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013;14:416–29.CrossRefPubMedGoogle Scholar
  11. 11.
    Petrova R, Joyner AL. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development. 2014;141:3445–57.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hanna A, Shevde LA. Hedgehog signaling: modulation of cancer properies and tumor mircroenvironment. Mol Cancer. 2016;15:35.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32.CrossRefGoogle Scholar
  14. 14.
    Keating GM. Vismodegib: in locally advanced or metastatic basal cell carcinoma. Drugs. 2012;72(11):1535–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Roche Registration Ltd. Erivedge 150 mg hard capsules: EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 6 Jul 2018.
  16. 16.
    Genentech Inc. ERIVEDGE® (vismodegib) capsule for oral use: US prescribing information. 2012. https://www.accessdata.fda.gov. Accessed 6 Jul 2018.
  17. 17.
    LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502–11.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19(19):5576–81.CrossRefPubMedGoogle Scholar
  19. 19.
    Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–72.CrossRefGoogle Scholar
  20. 20.
    Groenendijk FH, Bernards R. Drug resistance to targeted therapies: déjà vu all over again. Mol Oncol. 2014;8(6):1067–83.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Basset-Séguin N, Sharpe H, Poulalhon N, et al. Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma [abstract no. 9562]. J Clin Oncol. 2016;34(15 Suppl):9562.Google Scholar
  22. 22.
    Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327–41.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chang ALS, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–5.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Atwood SX, Sarin KY, Whitson RJ, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):342–53.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9(2):389–97.CrossRefPubMedGoogle Scholar
  26. 26.
    Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res. 2011;17(8):2512–20.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Graham RA, Hop CE, Borin MT, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol. 2012;74(5):788–96.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Graham RA, Lum BL, Morrison G, et al. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos. 2011;39(8):1460–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Sharma MR, Karrison TG, Kell B, et al. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013;19(11):3059–67.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    LoRusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(17):5774–82.CrossRefPubMedGoogle Scholar
  31. 31.
    Lu T, Wang B, Gao Y, et al. Semi-mechanism-based population pharmacokinetic modeling of the Hedgehog pathway inhibitor vismodegib. CPT Pharm Syst Pharmacol. 2015;4(11):680–9.CrossRefGoogle Scholar
  32. 32.
    Abou-Alfa GK, Lewis LD, LoRusso P, et al. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. Cancer Chemother Pharmacol. 2017;80(1):29–36.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Malhi V, Colburn D, Williams SJ, et al. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Cancer Chemother Pharmacol. 2016;78(1):41–9.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021–1026.e8.CrossRefPubMedGoogle Scholar
  36. 36.
    Sekulic A, Migden MR, Basset-Séguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Dréno B, Basset-Séguin N, Caro I, et al. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist. 2014;19(8):790–6.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Basset-Séguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729–36.CrossRefPubMedGoogle Scholar
  39. 39.
    Hansson J, Hauschild A, Kunstfeld R, et al. Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts) [abstract no. 9532]. J Clin Oncol. 2016;34(15 Suppl):9532.Google Scholar
  40. 40.
    Dummer R, Basset-Séguin N, Hansson J, et al. Impact of treatment breaks on vismodegib patient outcomes: exploratory analysis of the STEVIE study [abstract no. 9024]. J Clin Oncol. 2015;33(15 Suppl):9024.Google Scholar
  41. 41.
    Basset-Séguin N, Hansson J, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial [oral presentation]. In: 25th EADV Congress; 2016.Google Scholar
  42. 42.
    Grob J-J, Bartley K, Kuntsfeld R, et al. Assessment of quality of life (QoL) using Skindex-16 in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with vismodegib (VISMO) in the STEVIE study [abstract no. 3140]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB193.Google Scholar
  43. 43.
    Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–48.CrossRefPubMedGoogle Scholar
  44. 44.
    Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Lacouture M, Guillen J, Kudchadkar R, et al. The RegiSONIC Disease Registry Study: safety and effectiveness of vismodegib or surgery as primary treatment in patients with locally advanced basal cell carcinoma [abstract no. 3341]. Eur J Cancer. 2015;51(Suppl 3):S679–80.CrossRefGoogle Scholar
  46. 46.
    Lacouture ME, Guillen J, Kudchadkar R, et al. Management of common vismodegib (VISMO)-related adverse events in patients with locally advanced basal cell carcinoma (laBCC): RegiSONIC Disease Registry Study [abstract no. 3514]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB200.Google Scholar
  47. 47.
    Chang AL, Arron ST, Migden MR, et al. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016;11(1):120.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    US National Institutes of Health. ClinicalTrials.gov identifier NCT01604252. 2017. https://clinicaltrials.gov. Accessed 6 Jul 2018.
  49. 49.
    Sekulic A, Migden MR, Basset-Séguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update (30-month) of the pivotal ERIVANCE BCC study [abstract no. 9013]. J Clin Oncol. 2014;32(15 Suppl):9013.Google Scholar
  50. 50.
    Lacouture ME, Dreno B, Ascierto PA, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218–29.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Flohil SC, van der Leest RJ, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2013;49:2365–75.CrossRefPubMedGoogle Scholar
  52. 52.
    Bhutani T, Abrouk M, Sima CS, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017;77(4):713–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Lacouture M, Guillen J, Kudchadkar R, et al. Real-world treatment of vismodegib (VISMO)-related adverse events (AEs) in patients with locally advanced basal cell carcinoma: report from the RegiSONIC Disease Registry Study [abstract no. 3332]. Eur J Cancer. 2015;51(Suppl 3):S675.CrossRefGoogle Scholar
  54. 54.
    Edwards BJ, Raisch DW, Saraykar SS, et al. Hepatotoxicity with vismodegib: an MD Anderson Cancer Center and research on adverse drug events and reports project. Drugs R D. 2017;17(1):211–8.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Roche Products (New Zealand) Limited. Erivedge 150 mg hard capsules: New Zealand data sheet. http://www.medsafe.govt.nz. Accessed 29 June 2018.
  56. 56.
    Apalla Z, Papageorgiou C, Lallas A, et al. Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy. Clin Cosmet Investig Dermatol. 2017;10:171–7.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014;24(3):312–29.PubMedGoogle Scholar
  58. 58.
    Curis Inc. Curis announces full approval of Roche’s Erivedge® in the European Union [media release]. 28 Nov 2016. http://investors.curis.com.
  59. 59.
    McCusker M, Basset-Séguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50:774–83.CrossRefPubMedGoogle Scholar
  60. 60.
    Herms F, Luc H, Bagot M, et al. Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: a retrospective multicentric French study [abstract no. 9535]. J Clin Oncol. 2017;35(15 Suppl):9535.Google Scholar
  61. 61.
    Saintes C, Saint-Jean M, Brocard A, et al. Development of squamous cell carcinoma into basal cell carcinoma under treatment with vismodegib. J Eur Acad Dermatol Venereol. 2015;29(5):1006–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Basset-Seguin N. HPI resistance mechanisms and how to overcome it [abstract]. In: 13th EADO Congress; 2017.Google Scholar
  63. 63.
    Burness CB, Scott LJ. Sonidegib: a review in locally advanced basal cell carcinoma. Target Oncol. 2016;11(2):239–46.CrossRefPubMedGoogle Scholar
  64. 64.
    Gutzmer R, Sondak V, Migden M. Response to hedgehog pathway inhibitor therapy in patients with locally advanced basal cell carcinoma: composite assessments using 2 sets of response criteria [abstract]. In: 24th EADV Congress; 2015.Google Scholar
  65. 65.
    Danial C, Sarin KY, Oro AE, et al. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res. 2016;22(6):1325–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand
  2. 2.Department of Dermatology, Hôpital Saint LouisUniversité Paris 7ParisFrance

Personalised recommendations